Nexalis Therapeutics (ASX:NX1) General and Admin. Expense: A$0.27 Mil (TTM As of Dec. 2025)


What is Nexalis Therapeutics General and Admin. Expense?

Nexalis Therapeutics ASX:NX1 General and Admin. Expense is A$0.27 Mil as of Dec. 2025. The stock has 3 warning signs investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Nexalis Therapeutics's General and Admin. Expense for the six months ended in Dec. 2025 was A$0.24 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.27 Mil.

Nexalis Therapeutics General and Admin. Expense Related Terms

Nexalis Therapeutics General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for Nexalis Therapeutics's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nexalis Therapeutics General and Admin. Expense Chart

Nexalis Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.56 0.52 0.67 0.49 0.27

Nexalis Therapeutics Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.47 0.20 0.29 0.02 0.24

Nexalis Therapeutics General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.27 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of A$0.27 Mil mean?
Nexalis Therapeutics (ASX:NX1) has a General and Admin. Expense of A$0.27 Mil as of Dec. 2025. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Nexalis Therapeutics and its competitors.
Is Nexalis Therapeutics' General and Admin. Expense too high?
Nexalis Therapeutics' current General and Admin. Expense is A$0.27 Mil.
How does Nexalis Therapeutics' General and Admin. Expense compare to VRTX and REGN?
Nexalis Therapeutics' General and Admin. Expense of A$0.27 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Nexalis Therapeutics and its competitors. Nexalis Therapeutics's current General and Admin. Expense is A$0.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nexalis Therapeutics stock overvalued right now?
Nexalis Therapeutics (ASX:NX1) has a current General and Admin. Expense of A$0.27 Mil. The current General and Admin. Expense is A$0.27 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For Nexalis Therapeutics (ASX:NX1), the current General and Admin. Expense is A$0.27 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nexalis Therapeutics Business Description

Address 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000
Nexalis Therapeutics Ltd is an Australian clinical-stage drug development company that is focused on developing therapies to address unmet medical needs in pain management and mental health sectors. Its pipeline includes three clinical drug candidates focused on treatment-resistant depression (SRX-25), breakthrough cancer pain (IRX-211), and panic disorder (IRX-616a), each addressing areas of unmet medical need and potential commercial demand.